Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.

Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.

Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.

Vaccination is crucial for public health, but anti-vaccine movements are a concern.

Methotrexate for rheumatoid arthritis often causes side effects like diarrhea, fatigue, and hair loss, especially at higher doses.

Pharmacists play a crucial role in patient education and personalized care.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Adalimumab can cause complete hair loss in rare cases.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

More research is needed to understand and manage rheumatoid arthritis better.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

COVID-19 severely affects older adults with chronic heart, lung, or metabolic diseases.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

COVID-19 mRNA vaccines may increase the risk of flare-ups in certain inflammatory diseases.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

New treatments for alopecia areata show promise, but standardized guidelines are needed.

Microneedles could revolutionize pediatric medicine by offering painless drug delivery, but more development is needed.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Anti-TNF therapy can cause weight gain and hair loss, leading some patients to stop treatment.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Consider benefits and risks of new alopecia treatments for safety.

Watching, not removing, skin growths with moderate atypia and positive edges is okay; patients may get melanoma elsewhere, especially if they've had it before.

Platelet Rich Plasma can potentially help in restoring hair loss, but more research with larger groups is needed to confirm its effectiveness and standardize its use.

JSLE patients often have more hormone and metabolism issues, so regular check-ups and preventing obesity can help.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.